Navigation Links
Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Date:2/7/2011

MYSTIC, Conn. and DUBLIN, Feb. 7, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011. Amarin's participation includes both a panel discussion on Cardiology at 7:45am ET and a company presentation at 9:15am ET. The conference will be held at the Roosevelt Hotel in New York City.

A live audio webcast of the presentation will be available at the following URL:

http://www.wsw.com/webcast/leerink20/amrn

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.Investor Contact Information: Stephen SchultzInvestor Relations and Corporate CommunicationsAmarin CorporationIn U.S.: +1 (860) 572-4979 x292investor.relations@amarincorp.com Lee M. Stern The Trout Group In U.S.: +1 (646) 378-2922 lstern@troutgroup.comMedia Contact Information: David Schull or Martina Schwarzkopf, Ph.D. Russo Partners In U.S.:  +1 (212) 845-4271 or +1 (212) 845-4292 (office) +1 (347) 591-8785 (mobile) david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.comMark Swallow or David Dible Citigate Dewe Rogerson In U.K.: +44 (0)207 638 9571 mark.swallow@citigatedr.co.uk
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin to Present at UBS Life Sciences Conference
4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
6. Amarin Prices Public Offering of American Depositary Shares
7. Amarin Announces Underwriters Exercise of Over-Allotment Option
8. Amarin Announces Successful Completion of Offering of American Depositary Shares
9. Amarin Provides 2010 Year-End Review to Shareholders
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
Breaking Medicine News(10 mins):